Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference

Rhea-AI Summary

Caris Life Sciences (NASDAQ: CAI) will participate in the TD Cowen 46th Annual Health Care Conference held March 2-4, 2026 in Boston, Massachusetts. The company will present its precision medicine platform, AI/ML-enabled clinico-genomic capabilities, and recent corporate developments to investors and healthcare attendees.

Caris is headquartered in Irving, Texas, with global offices and provides comprehensive molecular profiling services including whole genome, whole exome and whole transcriptome sequencing.

Key Figures

Conference dates: March 2-4, 2026 Conference edition: 46th Media phone: 214.294.5606 +1 more

4 metrics

Conference dates March 2-4, 2026 TD Cowen 46th Annual Health Care Conference

Conference edition 46th TD Cowen Annual Health Care Conference

Media phone 214.294.5606 Corporate Communications contact number

Investor relations phone 917.689.3511 Investor Relations contact number

Market Reality Check

Price: $19.53 Vol: Volume 3,623,266 is 1.56x...

high vol

$19.53 Last Close

Volume Volume 3,623,266 is 1.56x the 20-day average of 2,319,543, indicating elevated trading activity ahead of a neutral conference update. high

Technical Shares at 19.53 are trading below the 200-day MA of 32.84 and sit 65.26% below the 52-week high and 4.08% above the 52-week low.

Peers on Argus

CAI fell 6.33% while key biotech peers showed mixed, mostly modest moves (e.g., ...

CAI fell 6.33% while key biotech peers showed mixed, mostly modest moves (e.g., MRNA +1.44%, ROIV -0.66%, HALO -1.02%), suggesting a stock‑specific reaction rather than a coordinated sector move.

Historical Context

5 past events · Latest: Feb 09 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 09	Earnings date notice	Neutral	+1.4%	Announced date and webcast details for Q4 and full-year 2025 results.
Jan 28	Clinical data update	Positive	+1.9%	Published large real-world study in T-DXd–treated metastatic breast cancer.
Jan 12	Preliminary earnings	Positive	-10.2%	Reported strong preliminary Q4 and 2025 revenue growth and cash levels.
Jan 12	Partnership announcement	Positive	-10.2%	Announced Everlywell partnership to launch Caris Detect MCED assay.
Jan 05	Conference participation	Neutral	-2.1%	Outlined plans to present at the J.P. Morgan Healthcare Conference.

Pattern Detected

Recent history shows mixed reactions: some positive scientific and partnership news aligned with gains, while strong preliminary financial results coincided with notable selloffs.

Recent Company History

Over the past few months, CAI has combined strong growth with active external visibility. Preliminary Q4 and full-year 2025 results on Jan 12, 2026 highlighted sharp revenue expansion but coincided with a -10.21% move. Partnership news the same day with Everlywell, tied to launching Caris Detect in the first half of 2026, also saw a -10.21% reaction. By contrast, a large real-world metastatic breast cancer data study on Jan 28, 2026 aligned with a +1.88% move. Today’s TD Cowen conference participation fits the pattern of ongoing investor outreach alongside scientific and financial updates.

Market Pulse Summary

This announcement highlights continued investor-relations outreach, as Caris participates in another...

Analysis

This announcement highlights continued investor-relations outreach, as Caris participates in another major healthcare conference following the J.P. Morgan event earlier in the year. The company has recently reported strong preliminary 2025 revenue growth and expanded partnerships, while also generating large real-world oncology datasets. At the same time, shares trade well below the 52-week high, and past news has triggered both rallies and sharp pullbacks. Observers may focus on how upcoming presentations and the late-February earnings release refine views on growth, execution, and capital positioning.

Key Terms

molecular profiling, whole genome, ai, machine learning, +2 more

6 terms

molecular profiling medical

"Through comprehensive molecular profiling (Whole Genome, Whole Exome and..."

Molecular profiling is a laboratory analysis that reads a patient’s disease at the level of genes, proteins or other molecules to reveal its specific characteristics—think of it as reading the instruction manual for a tumor or condition. For investors, it matters because the results guide which targeted treatments, diagnostics or tests will be used, shaping clinical demand, regulatory approval paths and potential revenue for companies developing precision medicines and companion tests.

whole genome medical

"Through comprehensive molecular profiling (Whole Genome, Whole Exome and..."

The whole genome is the complete set of an organism’s DNA — like a full instruction manual that contains every genetic recipe that makes the organism function. For investors, whole-genome information matters because it underpins diagnostics, drug targets, and personalized treatments; companies that can read or act on that full instruction manual may create new products, improve patient outcomes, or unlock revenue streams, affecting valuations and competitive position.

ai technical

"Through comprehensive molecular profiling..., advanced AI and machine learning, Caris has created..."

Artificial intelligence (AI) is technology that enables machines to mimic human thinking and learning, allowing them to analyze information, recognize patterns, and make decisions. For investors, AI matters because it can improve how businesses operate, create new products, or identify opportunities faster and more accurately than humans alone, potentially impacting company success and market trends.

machine learning technical

"Through comprehensive molecular profiling..., advanced AI and machine learning, Caris has created..."

Machine learning is a set of computer programs that learn patterns from large amounts of data and improve their predictions or decisions over time, like a recipe that gets better each time it’s adjusted based on taste tests. For investors it matters because these systems can speed up analysis, spot trends or risks humans might miss, automate routine work, and potentially create competitive advantages or cost savings that affect a company’s performance.

clinico-genomic medical

"created the large-scale, multimodal clinico-genomic database and computing capability..."

Clinico-genomic describes the combination of clinical patient information (symptoms, treatment outcomes, medical history) with genomic data (DNA changes and tumor genetics) to gain a fuller picture of disease and treatment response. For investors, this integrated approach can reveal which drugs are likely to work, identify new drug targets, and de-risk development programs — like fitting medical and genetic puzzle pieces together to predict which therapies will succeed in the market.

precision medicine medical

"a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer..."

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

AI-generated analysis. Not financial advice.

IRVING, Texas, Feb. 23, 2026 /PRNewswire/ -- Caris Life Sciences^® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will participate in the TD Cowen 46^th Annual Health Care Conference, which will be held March 2-4, 2026, in Boston, Massachusetts.

About Caris Life Sciences
Caris Life Sciences^® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.

Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 

Investor Relations:
IR@CarisLS.com
917.689.3511

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-participate-in-the-td-cowen-46th-annual-health-care-conference-302694075.html

SOURCE Caris Life Sciences

FAQ

When will Caris Life Sciences (CAI) present at the TD Cowen 46th Annual Health Care Conference?

Caris will participate at the conference on March 2-4, 2026 with sessions in Boston. According to the company, the event runs March 2-4, 2026, and Caris will engage with investors and industry attendees to discuss its precision medicine platform.

What will Caris Life Sciences (CAI) discuss at the TD Cowen March 2026 conference?

Caris will discuss its AI- and ML-enabled precision medicine platform and clinico-genomic database. According to the company, the presentation will highlight whole genome, whole exome and whole transcriptome sequencing and related diagnostic and drug-development capabilities.

How can investors access Caris Life Sciences (CAI) materials or contact investor relations around the TD Cowen event?

Investors can contact Caris investor relations via the provided IR email and phone. According to the company, IR@CarisLS.com and phone 917.689.3511 are available for investor inquiries and requests for presentation materials or meetings.

Where is Caris Life Sciences (CAI) headquartered and what services will it highlight at TD Cowen 2026?

Caris is headquartered in Irving, Texas and will highlight comprehensive molecular profiling services. According to the company, it will emphasize whole genome, whole exome and whole transcriptome sequencing plus AI-driven analysis for diagnosis and drug development.

Will Caris Life Sciences (CAI) discuss international operations at the TD Cowen conference in March 2026?

Caris will note its global footprint including offices in Phoenix, New York, Cambridge, Tokyo and Basel. According to the company, it provides services in the U.S. and other international markets through Caris or distributor partners.